Patents by Inventor David L. Linemeyer
David L. Linemeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030036633Abstract: DNAs encoding bradykinin B1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg10 kallidin and other B1-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: ApplicationFiled: October 22, 2001Publication date: February 20, 2003Applicant: Merck & Co., Inc.Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
-
Patent number: 6307027Abstract: DNAs encoding bradykinin B1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind desArg10 kallidin and other B1-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: May 10, 1999Date of Patent: October 23, 2001Assignee: Merck & Co., Inc.Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
-
Patent number: 5965367Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: September 17, 1997Date of Patent: October 12, 1999Assignee: Merck & Co., Inc.Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
-
Patent number: 5939263Abstract: A novel mammalian neuropeptide Y receptor and method of making the receptor are provided. The invention includes DNA encoding the receptor, the receptor, assays employing the receptor, cells expressing the receptor, antibodies which bind specifically to the receptor, RNA encoded by the DNA sequence or its complementary sequence, and single-stranded DNA with a sequence complementary to the RNA which encodes the receptor. The receptor and assays employing the receptor are useful for identifying compounds which bind to the receptor, including specific modulators of the receptor. Such compounds are useful for treating a variety of disease conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.Type: GrantFiled: July 25, 1997Date of Patent: August 17, 1999Assignee: Merck & Co., Ltd.Inventors: Margaret A. Cascieri, Douglas J. MacNeil, Lin-Lin Shiao, David H. Weinberg, Carina P. Tan, David L. Linemeyer, Catherine D. Strader
-
Patent number: 5712111Abstract: DNAs encoding bradykinin B.sub.1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg.sup.10 kallidin and other B.sub.1 -specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: April 15, 1994Date of Patent: January 27, 1998Assignee: Merck & Co., Inc.Inventors: David L. Linemeyer, John W. Hess, Joseph A. Borkowski, Kathleen K. Bierilo, John G. Menke
-
Patent number: 5621079Abstract: A novel mammalian neuropeptide Y receptor and method of making the receptor are provided. The invention includes DNA encoding the receptor, the receptor, assays employing the receptor, cells expressing the receptor, antibodies which bind specifically to the receptor, RNA encoded by the DNA sequence or its complementary sequence, and single-stranded DNA with a sequence complementary to the RNA which encodes the receptor. The receptor and assays employing the receptor are useful for identifying compounds which bind to the receptor, including specific modulators of the receptor. Such compounds are useful for treating a variety of disease conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.Type: GrantFiled: April 3, 1995Date of Patent: April 15, 1997Assignee: Merck & Co., Inc.Inventors: Margaret A. Cascieri, David L. Linemeyer, Douglas J. Macneil, Lin-Lin Shiao, Catherine D. Strader, David H. Weinberg, Carina P. Tan
-
Patent number: 5409897Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.Type: GrantFiled: January 31, 1994Date of Patent: April 25, 1995Assignee: Merck & Co., Inc.Inventors: Kenneth A. Thomas, David L. Linemeyer
-
Patent number: 5401832Abstract: Acidic fibroblast growth factor (aFGF) is isolated and purified from human brain tissue. The distinctive and complete amino acid sequences of both bovine and human aFGFs are determined and herein disclosed. Unique genes coding for these disclosed amino acid sequences are constructed. The bovine gene is derived from reverse translation of the aFGF amino acid sequence with unique restriction sites included while the human gene is derived by specific point mutations of the bovine gene. Each gene construct is inserted into an expression vector which is used to transform an appropriate host. The transformed host cells produce recombinant aFGF (r-aFGF), human or bovine, which is purified and has activity equivalent to the native protein. Both recombinant and purified brain-derived human and bovine aFGF are active mitogens for mesoderm and neuroectoderm-derived cells in culture, and promote wound healing of soft tissue, cartilaginous tissue and musculo-skeletal tissue.Type: GrantFiled: September 25, 1992Date of Patent: March 28, 1995Assignee: Merck & Co., Inc.Inventors: David L. Linemeyer, Linda J. Kelly, Guillermo Gimenez-Gallego, Kenneth A. Thomas, Jr.
-
Patent number: 5312911Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.Type: GrantFiled: March 12, 1993Date of Patent: May 17, 1994Assignee: Merck & Co., Inc.Inventors: Kenneth A. Thomas, David L. Linemeyer
-
Patent number: 5223483Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.Type: GrantFiled: August 28, 1992Date of Patent: June 29, 1993Assignee: Merck & Co., Inc.Inventors: Kenneth A. Thomas, David L. Linemeyer
-
Patent number: 5182298Abstract: This invention relates to compounds of structural formula (I) ##STR1## which are useful as Cholestrol lowering agents.Type: GrantFiled: March 18, 1991Date of Patent: January 26, 1993Assignee: Merck & Co., Inc.Inventors: Gregory L. Helms, Wendy S. Horn, E. Tracy T. Jones, David L. Linemeyer